MX2017009849A - Composiciones de profármaco de monometilfumarato. - Google Patents

Composiciones de profármaco de monometilfumarato.

Info

Publication number
MX2017009849A
MX2017009849A MX2017009849A MX2017009849A MX2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A
Authority
MX
Mexico
Prior art keywords
monomethylfumarate
prodrug compositions
formula
compositions
prodrug
Prior art date
Application number
MX2017009849A
Other languages
English (en)
Inventor
K Perkin Kristopher
Browning Ivan
S Manser David
Kirtikumar Shah Hardik
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54066160&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009849(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MX2017009849A publication Critical patent/MX2017009849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención proporciona composiciones farmacéuticas que comprenden compuestos de Fórmula (I) y los métodos para el tratamiento de trastornos neurológicos, que comprenden administrar a un sujeto que lo necesite una composición farmacéutica que comprende un compuesto de Fórmula (I). Ver fórmula.
MX2017009849A 2015-02-08 2015-03-10 Composiciones de profármaco de monometilfumarato. MX2017009849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113496P 2015-02-08 2015-02-08
PCT/IB2015/000731 WO2016124960A1 (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions

Publications (1)

Publication Number Publication Date
MX2017009849A true MX2017009849A (es) 2017-12-11

Family

ID=54066160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009849A MX2017009849A (es) 2015-02-08 2015-03-10 Composiciones de profármaco de monometilfumarato.

Country Status (24)

Country Link
US (3) US20160228376A1 (es)
EP (1) EP3253377B1 (es)
JP (3) JP2018503651A (es)
KR (1) KR102487136B1 (es)
CN (1) CN107205985A (es)
AU (3) AU2015381240A1 (es)
BR (1) BR112017016378A2 (es)
CA (1) CA2972179C (es)
CY (1) CY1124419T1 (es)
DK (1) DK3253377T3 (es)
EA (1) EA037666B1 (es)
ES (1) ES2879611T3 (es)
HR (1) HRP20211269T1 (es)
HU (1) HUE055210T2 (es)
IL (2) IL252962B (es)
LT (1) LT3253377T (es)
MX (1) MX2017009849A (es)
PL (1) PL3253377T3 (es)
PT (1) PT3253377T (es)
RS (1) RS62186B1 (es)
SG (3) SG10201907289VA (es)
SI (1) SI3253377T1 (es)
UA (1) UA121323C2 (es)
WO (1) WO2016124960A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200094485A (ko) * 2019-01-30 2020-08-07 (주)애거슨바이오 모노메틸 푸마레이트 전구체 약물 화합물 및 이들의 약학적 조성물
CN112020489B (zh) * 2019-03-29 2022-06-21 深圳仁泰医药科技有限公司 2-(2,5-二氧代吡咯烷-1基)乙基甲基富马酸酯的晶型a及其制备方法和应用
BR112021018452B1 (pt) * 2019-05-31 2022-10-04 Curacle Co., Ltd Comprimido de revestimento entérico e seu método de preparação
WO2021053476A1 (en) * 2019-09-16 2021-03-25 Glenmark Life Sciences Limited Process for preparation of diroximel fumarate
KR102566549B1 (ko) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
BR112023026276A2 (pt) * 2021-06-15 2024-03-05 Biogen Ma Inc Preparação sintética para fumarato de diroximel

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482547A (en) * 1982-08-26 1984-11-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted-1,3,4-benzotriazepines
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
RU2290946C2 (ru) 2001-01-12 2007-01-10 Фумафарм Аг Амиды фумаровой кислоты
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
MXPA06002657A (es) 2003-09-09 2006-06-05 Fumapharm Ag Uso de derivados de acido fumarico para el tratamiento de insuficiencia cardiaca y asma.
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2801354B1 (en) * 2004-10-08 2017-02-08 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
CA2610343A1 (en) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Release-control composition
WO2007042034A1 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
AU2007248473B2 (en) 2006-05-05 2011-01-27 The Regents Of The University Of Michigan Bivalent Smac mimetics and the uses thereof
CN104523673A (zh) 2009-04-29 2015-04-22 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
JP5733930B2 (ja) * 2009-09-09 2015-06-10 武田薬品工業株式会社 固形製剤
CN114146080A (zh) * 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
SI2970101T1 (sl) * 2013-03-14 2018-09-28 Alkermes Pharma Ireland Limited Prozdravila fumaratov in njihova uporaba pri zdravljenju različnih bolezni
US8669281B1 (en) * 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2015017762A1 (en) 2013-08-01 2015-02-05 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CN104027311A (zh) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 一种含有富马酸二甲酯的肠溶缓释微丸
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques

Also Published As

Publication number Publication date
AU2020205237B2 (en) 2022-04-14
KR20170115044A (ko) 2017-10-16
US20220257520A1 (en) 2022-08-18
HUE055210T2 (hu) 2021-11-29
UA121323C2 (uk) 2020-05-12
RS62186B1 (sr) 2021-08-31
CN107205985A (zh) 2017-09-26
WO2016124960A1 (en) 2016-08-11
SG10201907291QA (en) 2019-09-27
EA201791432A1 (ru) 2017-12-29
AU2015381240A1 (en) 2017-07-06
IL252962B (en) 2022-07-01
JP2018503651A (ja) 2018-02-08
CA2972179C (en) 2021-10-26
SG11201705124QA (en) 2017-07-28
HRP20211269T1 (hr) 2022-01-21
US20190247315A1 (en) 2019-08-15
BR112017016378A2 (pt) 2018-03-27
IL252962A0 (en) 2017-08-31
EP3253377B1 (en) 2021-05-12
EA037666B1 (ru) 2021-04-28
AU2020205237A1 (en) 2020-07-30
US20160228376A1 (en) 2016-08-11
JP2019031550A (ja) 2019-02-28
ES2879611T3 (es) 2021-11-22
CY1124419T1 (el) 2022-07-22
PT3253377T (pt) 2021-07-14
SI3253377T1 (sl) 2021-08-31
IL287830A (en) 2022-01-01
AU2019200868B2 (en) 2020-05-14
EP3253377A1 (en) 2017-12-13
SG10201907289VA (en) 2019-09-27
PL3253377T3 (pl) 2021-09-27
AU2019200868A1 (en) 2019-02-28
DK3253377T3 (da) 2021-07-12
JP2020203951A (ja) 2020-12-24
CA2972179A1 (en) 2016-08-11
KR102487136B1 (ko) 2023-01-10
LT3253377T (lt) 2021-08-25
JP7145918B2 (ja) 2022-10-03

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MY197698A (en) Oxysterols and methods of use thereof
MX2017014035A (es) Formas solidas novedosas.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2016008968A (es) Compuestos organicos.
TN2015000524A1 (en) Pharmaceutical compositions
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2016013108A (es) Nueva composicion para el tratamiento de la tricomoniasis.